PR Newswire
NEWTOWN, Pa.
, July 6, 2025 /PRNewswire/ — Edelson Lechtzin LLP, a leading class action law firm, is investigating securities fraud claims on behalf of all investors of Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS) who purchased stock pursuant to and/or traceable to Hims & Hers’ statement announcing its long-term partnership with Novo Nordisk A/S on April 29, 2025. To consult with a lawyer about this case, go HERE.
Investors who purchased Hims & Hers stock may move the U.S. District Court for the Northern District of California to appoint them as a lead plaintiff, no later than August 25, 2025. Please contact Edelson Lechtzin LLP at 844-696-7492ext. 1, or by email at [email protected] to discuss your investment losses.
Background on Hims & Hers Health, Inc.
Hims & Hers is a telehealth and online pharmacy company that offers prescription and over-the-counter medications, mental health services, and personal care products through a direct-to-consumer platform in the U.S. and the U.K.
The Securities Fraud Claims.
The Complaint alleges that Hims & Hers made materially false and misleading statements and failed to disclose material facts about its partnership with Novo Nordisk between April 29, 2025, and June 23, 2025 (the “Class Period”). Specifically, Hims allegedly failed to disclose that (1) it engaged in the deceptive promotion and sale of Novo Nordisk’s Wegovy® weight loss drug, and (2) this deception created a substantial risk that the company’s partnership with Novo Nordisk would be terminated.
On April 29, 2025, Hims & Hers issued a press release announcing a long-term collaboration with Novo Nordisk, starting with the immediate sale of “a bundled offering of Novo Nordisk’s FDA-approved Wegovy® on the Hims & Hers platform.” However, on June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims, asserting Hims “failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of ‘personalization’ and are disseminating deceptive marketing that put[s] patient safety at risk.”
Following Novo Nordisk’s termination announcement, the price of Hims & Hers stock fell $22.24 per share, or 34.63%, to close at $41.98 per share on June 23, 2025.
ABOUT EDELSON LECHTZIN LLP: Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to cases involving securities and investment fraud, our lawyers focus on class cases alleging violations of the federal antitrust laws, employee benefit plans under ERISA, wage theft, data security, and consumer protection.
For more information, please contact:
Marc H. Edelson, Esq.
Eric Lechtzin, Esq.
EDELSON LECHTZIN LLP
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492 or 215-867-2399 ext. 1
Email: [email protected]
Email: [email protected]
Web: www.edelson-law.com
This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. Your ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
View original content to download multimedia:https://www.prnewswire.com/news-releases/hims-investor-alert-edelson-lechtzin-llp-urges-hims–hers-health-inc-nyse-hims-shareholders-to-consult-an-attorney-about-the-impending-lead-plaintiff-deadline-in-the-securities-fraud-class-action-302498564.html
SOURCE Edelson Lechtzin LLP
